Sunshine Biopharma Inc. Announces Warrant Exercise Price Reduced to $1.2202

What Happened
Sunshine Biopharma Inc. (filed 8‑K on 2026-08-03) announced that, as of the filing date, the exercise price of its outstanding Series B Warrants has been reduced to $1.2202. The company says the reduction was caused by recent sales of its common stock under its previously disclosed at‑the‑market (ATM) offering. The new exercise price is subject to further adjustment under the terms of the Series B Warrants.

Key Details

• Filing: Form 8‑K, Item 8.01 (Other Events), filed August 3, 2026.
• New exercise price for Series B Warrants: $1.2202 (effective as of the filing date).
• Cause: Recent sales of common stock under the company’s previously disclosed at‑the‑market offering.
• Note: The exercise price may be further adjusted according to the Series B Warrant terms.

Why It Matters
A lower exercise price makes it cheaper for warrant holders to buy Sunshine Biopharma common shares, which can increase the likelihood of warrant exercise and potential dilution of existing shareholders if exercised. The adjustment is a mechanical result of the ATM sales per the warrant agreement; investors should review the Series B Warrant terms and monitor future company disclosures for any additional adjustments or related equity changes. This 8‑K does not report earnings or management changes.